About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Gck
glucokinase
MGI:1270854
53 phenotypes from 31 alleles in 25 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
Gckem1(IMPC)H/Gck+
C57BL/6NTac-Gckem1(IMPC)H/H 		impaired glucose tolerance J:211773
increased circulating alkaline phosphatase level J:211773
increased circulating fructosamine level J:211773
increased circulating glucose level J:211773
increased fasting circulating glucose level J:211773
Gckem1(IMPC)H/Gckem1(IMPC)H
C57BL/6NTac-Gckem1(IMPC)H/H 		preweaning lethality, incomplete penetrance J:211773
GckGena348/Gck+
involves: BALB/c * C3H/He 		hyperglycemia J:79719, J:82809, J:90389
impaired glucose tolerance J:90389
increased body weight J:82809
GckGena348/GckGena348
involves: BALB/c * C3H/He 		hyperglycemia J:90389
impaired glucose tolerance J:90389
GckGls006/Gck+
C3HeB/FeJ-GckGls006 		decreased circulating insulin level J:189544
decreased glucokinase activity J:189544
decreased insulin secretion J:189544
decreased pancreatic beta cell mass J:189544
normal homeostasis/metabolism phenotype J:189544
hyperglycemia J:189544
impaired glucose tolerance J:189544
increased circulating glucose level J:189544
small pancreatic islets J:189544
GckGls006/GckGls006
C3HeB/FeJ-GckGls006 		abnormal pancreatic beta cell morphology J:189544
abnormal pancreatic islet morphology J:189544
decreased body weight J:189544
decreased glucokinase activity J:189544
decreased pancreatic beta cell mass J:189544
hyperglycemia J:137483, J:189544
increased circulating glucose level J:189544
normal mortality/aging J:189544
small pancreatic islets J:189544
GckHlb62/?
C57BL/6J-GckHlb62/J 		hyperglycemia J:82961, J:214141
impaired glucose tolerance J:214141
GckM1Btlr/Gck+
C57BL/6J-GckM1Btlr 		impaired glucose tolerance J:221479
GckM1Btlr/GckM1Btlr
C57BL/6J-GckM1Btlr 		impaired glucose tolerance J:221479
Gckm1Rge/Gck+
involves: C3HeB/FeJ 		decreased insulin secretion J:162903
decreased pancreatic beta cell mass J:162903
hyperglycemia J:162903
impaired glucose tolerance J:162903
increased circulating insulin level J:162903
insulin resistance J:162903
small pancreatic islets J:162903
Gckm1Rge/Gckm1Rge
involves: C3HeB/FeJ 		decreased body weight J:162903
hyperglycemia J:162903
increased urine glucose level J:162903
postnatal growth retardation J:162903
postnatal lethality J:162903
Gckm2Btlr/Gckm2Btlr
C57BL/6J-Gckm2Btlr 		impaired glucose tolerance J:264650
GckRgsc149/Gck+
involves: C57BL/6J * DBA/2J 		hyperglycemia J:88919
increased glycosylated hemoglobin level J:88919
GckRgsc149/Gck+
involves: C57BL/6JJcl * DBA/2JJcl 		hyperglycemia J:133634
GckRgsc210/Gck+
involves: C57BL/6J * DBA/2J 		hyperglycemia J:88919
impaired glucose tolerance J:88919
increased glycosylated hemoglobin level J:88919
GckRgsc210/GckRgsc210
involves: C57BL/6J * DBA/2J 		decreased body weight J:88919
decreased liver glycogen level J:88919
hepatic steatosis J:88919
hyperglycemia J:88919
increased urine glucose level J:88919
postnatal lethality J:88919
GckRgsc236/Gck+
involves: C57BL/6J * DBA/2J 		hyperglycemia J:88919
increased glycosylated hemoglobin level J:88919
GckRgsc272/Gck+
involves: C57BL/6J * DBA/2J 		decreased circulating insulin level J:88919
hyperglycemia J:88919
impaired glucose tolerance J:88919
increased glycosylated hemoglobin level J:88919
GckRgsc341/Gck+
involves: C57BL/6J * DBA/2J 		hyperglycemia J:88919
impaired glucose tolerance J:88919
increased glycosylated hemoglobin level J:88919
GckRgsc392/Gck+
involves: C57BL/6J * DBA/2J 		decreased circulating insulin level J:88919
hyperglycemia J:88919
impaired glucose tolerance J:88919
increased glycosylated hemoglobin level J:88919
GckRgsc392/GckRgsc392
involves: C57BL/6J * DBA/2J 		decreased body weight J:88919
decreased liver glycogen level J:88919
hepatic steatosis J:88919
hyperglycemia J:88919
GckRgsc475/Gck+
involves: C57BL/6J * DBA/2J 		decreased circulating insulin level J:88919
hyperglycemia J:88919
impaired glucose tolerance J:88919
increased glycosylated hemoglobin level J:88919
GckRgsc552/Gck+
involves: C57BL/6J * DBA/2J 		hyperglycemia J:88919
increased glycosylated hemoglobin level J:88919
GckRgsc553/Gck+
involves: C57BL/6J * DBA/2J 		hyperglycemia J:88919
increased glycosylated hemoglobin level J:88919
GckRgsc702/Gck+
involves: C57BL/6J * DBA/2J 		decreased circulating insulin level J:88919
hyperglycemia J:88919
impaired glucose tolerance J:88919
increased glycosylated hemoglobin level J:88919
GckRgsc702/GckRgsc702
involves: C57BL/6J * DBA/2J 		decreased body weight J:88919
decreased liver glycogen level J:88919
hepatic steatosis J:88919
hyperglycemia J:88919
increased urine glucose level J:88919
postnatal lethality J:88919
GckRgsc735/Gck+
involves: C57BL/6J * DBA/2J 		hyperglycemia J:88919
increased glycosylated hemoglobin level J:88919
GckRgsc960/Gck+
involves: C57BL/6JJcl * DBA/2JJcl 		hyperglycemia J:133634
GckSgrd-2Nwu/Gck+
C57BL/6J-GckSgrd-2Nwu 		hyperglycemia J:196563
GckSgrd-2Nwu/GckSgrd-2Nwu
C57BL/6J-GckSgrd-2Nwu 		decreased circulating insulin level J:196563
hyperglycemia J:196563
GckSgrd/Gck+
C57BL/6J-GckSgrd 		decreased circulating insulin level J:196563
hyperglycemia J:196563
GckSgrd/GckSgrd-2Nwu
C57BL/6J-GckSgrd/GckSgrd-2Nwu 		decreased circulating insulin level J:196563
hyperglycemia J:196563
GckSgrd/GckSgrd
C57BL/6J-GckSgrd 		decreased circulating insulin level J:196563
hyperglycemia J:196563
Gcktm1.1Mgn/Gck+
Tg(Ins2-cre)25Mgn/0
involves: 129S6/SvEvTac * C57BL/6 * DBA/2 		decreased glycogen level J:51826
decreased insulin secretion J:51826
hyperglycemia J:51826
impaired glucose tolerance J:51826
Gcktm1.1Mgn/Gcktm1.1Mgn
129S6/SvEvTac-Gcktm1.1Mgn 		increased circulating glucose level J:51826
Gcktm1.1Mgn/Gcktm1.1Mgn
involves: 129S6/SvEvTac * C57BL/6 		increased circulating glucose level J:51826
Gcktm1.1Mgn/Gcktm1.1Mgn
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129S6/SvEvTac * C57BL/6 * DBA/2 		abnormal glucose homeostasis J:51826
decreased glycogen level J:51826
decreased insulin secretion J:51826
impaired glucose tolerance J:51826
increased circulating glucose level J:51826
increased circulating insulin level J:51826
insulin resistance J:51826
Gcktm1.1Mgn/Gcktm1.1Mgn
Tg(Ins2-cre)25Mgn/0
involves: 129S6/SvEvTac * C57BL/6 * DBA/2 		decreased circulating insulin level J:51826
decreased liver glycogen level J:51826
hepatic steatosis J:51826
hyperglycemia J:51826
neonatal lethality, incomplete penetrance J:51826
Gcktm1.2Mgn/Gck+
involves: 129S6/SvEvTac * C57BL/6 		decreased insulin secretion J:51826
decreased liver glycogen level J:51826
hepatic steatosis J:51826
hyperglycemia J:51826
impaired glucose tolerance J:51826
Gcktm1.2Mgn/Gcktm1.2Mgn
involves: 129S6/SvEvTac * C57BL/6 		decreased circulating insulin level J:51826
decreased liver glycogen level J:51826
hepatic steatosis J:51826
hyperglycemia J:51826
increased circulating free fatty acids level J:51826
postnatal lethality, complete penetrance J:51826
Gcktm1Efr/Gck+
involves: 129P2/OlaHsd * C57BL/6 		abnormal glucose homeostasis J:28756
hyperglycemia J:28756
impaired glucose tolerance J:28756
Gcktm1Efr/Gcktm1Efr
involves: 129P2/OlaHsd * C57BL/6 		embryonic lethality during organogenesis, incomplete penetrance J:28756
Gcktm1Hrt/Gck+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: C57BL/6 * DBA 		abnormal heart echocardiography feature J:250069
abnormal mitochondrial crista morphology J:250069
abnormal pancreatic beta cell physiology J:250069
cardiac fibrosis J:250069
impaired glucose tolerance J:105247, J:250069
increased circulating glucose level J:105247
increased fasting circulating glucose level J:250069
increased mitochondrial number J:250069
insulin resistance J:250069
prolonged PR interval J:250069
prolonged QRS complex duration J:250069
Gcktm1Mgn/Gcktm1Mgn
involves: 129S6/SvEvTac * C57BL/6 		increased circulating glucose level J:51826
Gcktm1Tka/Gck+
involves: 129X1/SvJ * ICR 		decreased insulin secretion J:30334
hyperglycemia J:30334
impaired glucose tolerance J:30334
increased urine glucose level J:30334
Gcktm1Tka/Gcktm1Tka
involves: 129X1/SvJ * ICR 		abnormal pancreatic beta cell physiology J:30334
decreased circulating insulin level J:30334
decreased insulin secretion J:30334
normal endocrine/exocrine gland phenotype J:30334
hepatic steatosis J:30334
hyperglycemia J:30334
increased urine glucose level J:30334
ketosis J:30334
postnatal growth retardation J:30334
postnatal lethality, complete penetrance J:30334
Gcktm1Ts/Gck+
either: (involves: 129S7/SvEvBrd * C57BL/6J) or (involves: 129S7/SvEvBrd * DBA/2J) 		hyperglycemia J:29255
impaired glucose tolerance J:29255
Gcktm1Ts/Gcktm1Ts
either: (involves: 129S7/SvEvBrd * C57BL/6J) or (involves: 129S7/SvEvBrd * DBA/2J) 		abnormal circulating cholesterol level J:29255
decreased liver glycogen level J:29255
increased circulating triglyceride level J:29255
microvesicular hepatic steatosis J:29255
postnatal lethality, complete penetrance J:29255
Gcktm1Ydor/Gck+
Tg(Ins2-cre)25Mgn/0
involves: C57BL/6 * C57BL/6J * DBA 		abnormal endocrine pancreas physiology J:302600
abnormal pancreatic beta cell physiology J:302600
decreased fasting circulating glucose level J:302600
decreased pancreatic beta cell mass J:302600
hypoglycemia J:302600
impaired glucose tolerance J:302600
increased circulating insulin level J:302600
increased insulin secretion J:302600
increased pancreatic beta cell mass J:302600
increased pancreatic beta cell proliferation J:302600
Gcktm1Ydor/Gck+
Tg(Ins1-cre/ERT)1Lphi/0
involves: C57BL/6 * C57BL/6J * CD-1 		hypoglycemia J:302600
impaired glucose tolerance J:302600
increased pancreatic beta cell mass J:302600
Gcktm2Mgn/Gck+
129S6/SvEvTac-Gcktm2Mgn 		abnormal glucose homeostasis J:121910
abnormal insulin secretion J:121910
decreased glucokinase activity J:121910
normal endocrine/exocrine gland phenotype J:121910
hyperglycemia J:121910
impaired glucose tolerance J:121910
Gcktm2Mgn/Gck+
B6.129S6-Gcktm2Mgn 		hyperglycemia J:121910
Gcktm2Mgn/Gcktm2Mgn
129S6/SvEvTac-Gcktm2Mgn 		hyperglycemia J:121910
postnatal lethality, complete penetrance J:121910
Gcktm3Mgn/Gck+
129S6/SvEvTac-Gcktm3Mgn 		abnormal glucose homeostasis J:121910
abnormal insulin secretion J:121910
decreased glucokinase activity J:121910
normal endocrine/exocrine gland phenotype J:121910
hypoglycemia J:121910
Gcktm3Mgn/Gck+
B6.129S6-Gcktm3Mgn 		hypoglycemia J:121910
Gcktm3Mgn/Gcktm3Mgn
129S6/SvEvTac-Gcktm3Mgn 		abnormal circulating insulin level J:121910
abnormal glucose homeostasis J:121910
abnormal insulin secretion J:121910
decreased circulating glucose level J:121910
decreased glucokinase activity J:121910
hypoglycemia J:121910
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory